Literature DB >> 12540967

Vascular endothelial growth factor enhances venous thrombus recanalisation and organisation.

Matthew Waltham1, Kevin G Burnand, Michael Collins, Catharine L McGuinness, Inderjit Singh, Alberto Smith.   

Abstract

Vascular endothelial growth factor (VEGF) is a regulator of physiological and pathological angiogenesis and is found in naturally resolving experimental venous thrombi, where it may also regulate recanalisation. In this study VEGF protein was injected into venous thrombi to determine if this enhanced recanalisation and organisation. A rat model of inferior vena cava (IVC) thrombosis was used. Thrombi were formed in 3 groups (n = 3 per group). 10 micro l (125)I-VEGF was directly injected into thrombus thirty minutes after induction. Three hours, 1 day and 6 days later thrombus, IVC, and other tissues were harvested. (125)I-VEGF was mostly distributed in the thrombus and the IVC, with smaller amounts in other tissues. Thrombi were formed in a further 4 groups (n = 6 per group). Thirty minutes after induction control solution or 1 ng, 10 ng or 100 ng recombinant human VEGF(165) was injected directly into the thrombus. Lumen recanalisation, thrombus organisation and monocyte content were measured on digitised sections by image analysis. In animals treated with 10 ng of VEGF there was a greater area of lumen recanalisation [mean 5492 pixels, standard error of mean (sem) 922] compared to controls (mean 2974, sem 385) (P = 0.005). There was a significant increase in the organisation score in all treated animals (1 ng: mean 70, sem 1.7, P = 0.0025; 10 ng: mean 70, sem 2.0, P = 0.0042; 100 ng: mean 72, sem 1.9, P = 0.0003) compared to controls (mean 63, sem 1.7). The monocyte content was lower in the animals treated with 1 ng VEGF (mean 3.8% of thrombus area, sem 0.3%) compared to controls (mean 5.5%, sem 0.4%) (P = 0.0008). The proportion of monocytes migrating to the centre of the thrombus increased in a dose-related manner. VEGF may prove to be of use in the treatment of venous thrombosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12540967

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

Review 1.  Approach to chemotherapy-associated thrombosis.

Authors:  Peter Oppelt; Anthony Betbadal; Lalitha Nayak
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

2.  Endovascular Treatment with Platinum Coils. Recanalization is Associated with Early Increased von Willebrand Factor mRNA.

Authors:  J Raymond; C Ogoudikpe; A Metcalfe; I Salazkin; G Gevry; O Robledo
Journal:  Interv Neuroradiol       Date:  2006-07-31       Impact factor: 1.610

Review 3.  Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms.

Authors:  Sarah Medrek; Zeenat Safdar
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

Review 4.  Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension.

Authors:  Daniel T Matthews; Anna R Hemnes
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

5.  Upregulation of hypoxia-inducible factor 1 alpha in local vein wall is associated with enhanced venous thrombus resolution.

Authors:  Colin E Evans; Julia Humphries; Matthew Waltham; Prakash Saha; Katherine Mattock; Ashish Patel; Anwar Ahmad; Ashar Wadoodi; Bijan Modarai; Kevin Burnand; Alberto Smith
Journal:  Thromb Res       Date:  2011-05-31       Impact factor: 3.944

6.  Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.

Authors:  Julia Humphries; James A Gossage; Bijan Modarai; Kevin G Burnand; Thomas H Sisson; Colin Murdoch; Alberto Smith
Journal:  J Vasc Surg       Date:  2009-08-22       Impact factor: 4.268

Review 7.  Leukocytes and the natural history of deep vein thrombosis: current concepts and future directions.

Authors:  Prakash Saha; Julia Humphries; Bijan Modarai; Katherine Mattock; Matthew Waltham; Colin E Evans; Anwar Ahmad; Ashish S Patel; Sobath Premaratne; Oliver T A Lyons; Alberto Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03       Impact factor: 8.311

8.  Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor.

Authors:  Derek Klarin; Connor A Emdin; Pradeep Natarajan; Mark F Conrad; Sekar Kathiresan
Journal:  Circ Cardiovasc Genet       Date:  2017-04

9.  Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension.

Authors:  Sherin Alias; Bassam Redwan; Adelheid Panzenboeck; Max P Winter; Uwe Schubert; Robert Voswinckel; Maria K Frey; Johannes Jakowitsch; Arman Alimohammadi; Lukas Hobohm; Andreas Mangold; Helga Bergmeister; Maria Sibilia; Erwin F Wagner; Eckhard Mayer; Walter Klepetko; Thomas J Hoelzenbein; Klaus T Preissner; Irene M Lang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-02-13       Impact factor: 8.311

10.  Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells.

Authors:  David M Smadja; Agnès Basire; Aymeric Amelot; Aurélie Conte; Ivan Bièche; Bernard F Le Bonniec; Martine Aiach; Pascale Gaussem
Journal:  J Cell Mol Med       Date:  2008-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.